Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein

Journal of Virology

Volumn 89, Issue 13, 2015, Pages 6835-6847

  Cullen, Lori McGinnes ^a   Schmidt, Madelyn R ^a   Kenward, Sarah A ^a   Woodland, Robert T ^a   Morrison, Trudy G ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; F PROTEIN; F PROTEIN ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VLP PROTEIN; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOGLOBULIN G; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS FUSION PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINE PRODUCTION; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; IMMUNOLOGY; NEWCASTLE DISEASE VIRUS; SERODIAGNOSIS;

MURINAE; MUS; NEWCASTLE DISEASE VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN G; MICE, INBRED BALB C; NEUTRALIZATION TESTS; NEWCASTLE DISEASE VIRUS; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS;

EID: 84930894006     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00384-15     Document Type: Article

References (46)

1. Karron RA. 2008. Respiratory syncytial virus and parainfluenza virus vaccines, 5th ed. Saunders-Elsevier, Philadelphia, PA.
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EAF, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
3. Han LL, Alexander JP, Anderson LJ. 1999. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 179:25-30. http://dx.doi.org/10.1086/314567.
4. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. NEngl J Med 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
5. Falsey AR, Walsh EE. 2000. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13:371-384. http://dx.doi.org/10.1128/CMR .13.3.371-384.2000.
6. Raboni SM, Nogueira MB, Tsuchiya LR, Takahashi GA, Pereira LA, Pasquini R, Siqueira MM. 2003. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 76:142-146. http://dx.doi .org/10.1097/01.TP.0000072012.26176.58.
7. Walsh EE, Falsey AR, Hennessey PA. 1999. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med 160:791-795. http://dx.doi.org/10.1164/ajrccm.160.3.9901004.
8. Graham BS. 2011. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239:149-166. http://dx.doi.org/10.1111/j.1600-065X.2010.00972.x.
9. Karron RA, Buchholz UJ, Colline PL. 2013. Live-attenuated respiratory syncytial virus vaccines, p 259-284. In Anderson LJ, Graham BS (ed), Challenges and opportunities for respiratory syncytial virus vaccines. Springer, Heidelberg, Germany.
10. Morrison TG, Walsh EE. 2013. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus, p 285-306. In Anderson LJ, Graham BS (ed), Challenges and opportunities for respiratory syncytial virus vaccines. Springer, Heidelberg, Germany.
11. Power UF. 2008. Respiratory syncytial virus (RSV) vaccines-two steps back for one leap forward. J Clin Virol 41:38-44. http://dx.doi.org/10.1016/j.jcv.2007.10.024.
12. Jardetzky TS, Lamb RA. 2004. A class act. Nature 427:307-308. http://dx .doi.org/10.1038/427307a.
13. Smith EC, Popa A, Chang A, Masante C, Dutch RE. 2009. Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J 276:7217-7227. http://dx.doi.org/10.1111/j.1742-4658.2009.07401.x.
14. Lamb RA, Parks GD. 2007. Paramyxoviridae: the viruses and their replication, p 1450-1496. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
15. Yin H-S, Paterson RG, Wen X, Lamb RA, Jardetzky TS. 2005. Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci U S A 102:9288-9293. http://dx.doi.org/10.1073/pnas.0503989102.
16. Yin H-S, Wen X, Paterson RG, Lamb RA, Jardetzky TS. 2006. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38-44. http://dx.doi.org/10.1038/nature04322.
17. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108:9619-9624. http://dx.doi.org/10.1073/pnas.1106536108.
18. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. http://dx.doi.org/10.1128/JVI.00555-11.
19. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. http://dx.doi.org/10.1126/science.1234914.
20. Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M, Zhou B, Lu H, Boddapati S, Li J, Flyer D, Glenn G. 2012. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 7:e50852. http://dx.doi.org/10.1371/journal.pone.0050852.
21. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C. 2012. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 109:3089-3094. http://dx.doi.org/10.1073/pnas.1115941109.
22. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang G-Y, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko S-Y, Todd J-P, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. http://dx.doi.org/10.1126/science.1243283.
23. Jennings GT, Bachmann MF. 2008. The coming of age of virus-like particle vaccines. Biol Chem 389:521-536. http://dx.doi.org/10.1515/BC .2008.064.
24. Noad R, Roy P. 2003. Virus-like particles as immunogens. Trends Microbiol 11:438-444. http://dx.doi.org/10.1016/S0966-842X(03)00208-7.
25. Bachmann MF, Jennings GT. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787-796. http://dx.doi.org/10.1038/nri2868.
26. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare M, Smith G, Heaton PM, Fraire A, Morrison TG. 2010. Newcastle disease virus-like particles containing respiratory syncytial virusGprotein induced protection in BALB/c mice with no evidence of immunopathology. J Virol 84:1110-1123. http://dx.doi.org/10.1128/JVI.01709-09.
27. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG. 2011. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 85:366-377. http://dx .doi.org/10.1128/JVI.01861-10.
28. Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. 2014. Modification of the respiratory syncytial virus F protein in virus-like particles impacts generation of B cell memory. J Virol 88:10165-10176. http://dx.doi.org/10.1128/JVI.01250-14.
29. Connors M, Collins PL, Firestone C-Y, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484. http://dx.doi.org/10.1016/0264-410X(92)90397-3.
30. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang H-Y, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. NatMed 15:34-41. http://dx.doi.org/10.1038/nm.1894.
31. Pantua HD, McGinnes LW, Peeples ME, Morrison TG. 2006. Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol 80:11062-11073. http://dx.doi.org/10.1128/JVI.00726-06.
32. Frank S, Kammerer RA, Mechling D, Schulthess T, Landwehr R, Bann J, Guo Y, Lustig A, Bachinger HP, Engel J. 2001. Stabilization of short collagen-like triple helices by protein engineering. J Mol Biol 308:1081-1089. http://dx.doi.org/10.1006/jmbi.2001.4644.
33. McGinnes LW, Morrison TG. 2013. Newcastle disease virus-like particles:preparation, purification, quantification, and incorporation of foreign glycoproteins, current protocols in microbiology. John Wiley and Sons, Inc., Hoboken, NJ.
34. Beeler JA, van Wyke Coelingh K. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63:2941-2950.
35. Jain S, McGinnes LW, Morrison TG. 2007. Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein. J Virol 81:2328-2339. http://dx.doi.org/10.1128/JVI.01940-06.
36. Jain S, McGinnes LW, Morrison TG. 2008. Overexpression of thiol/disulfide isomerases enhances membrane fusion directed by Newcastle disease virus fusion protein. J Virol 82:12039-12048. http://dx.doi.org/10.1128/JVI.01406-08.
37. Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. 2009. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 83:1492-1500. http://dx.doi.org/10.1128/JVI.00671-08.
38. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. 2010. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 17:248-250. http://dx.doi.org/10.1038/nsmb.1723.
39. McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, Morrison TG. 2010. Assembly and biological and immunological properties of Newcastle disease virus-like particles. J Virol 84:4513-4523. http://dx.doi.org/10.1128/JVI.01931-09.
40. Miroshnikov KA, Marusich EI, Cerritelli ME, Cheng N, Hyde CC, Steven AC, Mesyanzhinov VV. 1998. Engineering trimeric fibrous proteins based on bacteriophage T4 adhesins. Protein Eng 11:329-332. http://dx.doi.org/10.1093/protein/11.4.329.
41. Leyrat C, Paesen GC, Charleston J, Renner M, Grimes JM. 2014. Structural insights into the human metapneumovirus glycoprotein ectodomain. J Virol 88:11611-11616. http://dx.doi.org/10.1128/JVI.01726-14.
42. Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW. 2003. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multicenter trial in children with cystic fibrosis. Vaccine 21:2448-2460. http://dx.doi.org/10.1016/S0264-410X(03)00098-7.
43. Jennings GT, Bachmann MF. 2007. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med 7:143-155. http://dx.doi.org/10.2174/156652407780059140.
44. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. 2013. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 110:11133-11138. http://dx.doi.org/10.1073/pnas.1309070110.
45. Cardenas S, Auais A, Piedimonte G. 2005. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 3:719-726. http://dx.doi.org/10.1586/14787210.3.5.719.
46. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, LKJ. 2007. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 151:34-42. http://dx .doi.org/10.1016/j.jpeds.2007.02.032.